How Early Safety Testing Can Save Lives And Billions

Most new medicines fail long before they help a single patient. We dig into a bold idea: what if hidden contamination, not weak efficacy, silently derails far too many trials—and what if human immune cell tests could spot danger early enough to change the odds?Our guest, Dr. Moyer, shares how a life upended by civil war led to a career in biology and a mission to make drug safety human-centric. We compare standard sterility and endotoxin testing with human cell–based pyrogen assays that measure cytokine responses to any bioactive contaminant, even those beyond PCR or antibody reach. He explains why mice often miss short‑term pyrogen signals, how non-linear biology demands smarter analysis, and how his lab builds pathogenicity profiles to reveal risks that linear models smooth away. The result: faster, clearer answers on safety that let teams focus on efficacy and help regulators move with confidence.We also connect safety to justice. When one approved drug carries the cost of nine failures, prices rise and access shrinks. Early, comprehensive safety screening can lower waste, reduce adverse events, and support fairer care. Dr. Moyer opens up about leaving academia, surviving funding droughts, and earning trust by delivering careful, reproducible results. We talk about AI’s promise and limits in biology, the damage done by data secrecy, and why representation in biotech leadership matters for the questions we ask and the patients we serve.We close with a call to build the pipeline of future scientists through joyful early learning, including a new children’s book that makes glucose and insulin exciting for kids. Subscribe, share this with a friend who cares about safer medicines, and leave a review with your take—should failure data be public by default? Your feedback helps us bring more rigorous, human-centered science to the forefront.Support the show